A tumour vaccine of fixed tumour fragments in a controlled-release vehicle with cytokines for therapy of hepatoma in mice. セルメディシン株式会社が紹介する自家がんワクチン療法に関する記事や、論文をご覧いただけます。

会社情報

紹介記事・論文

A tumour vaccine of fixed tumour fragments in a controlled-release vehicle with cytokines for therapy of hepatoma in mice.

Authors:Kushida S, Peng BG, Uchimura E, Kuang M, Huang L, Miwa M, Ohno T.

Journal:Dig Liver Dis. 2004 Jul;36(7):478-85.

Abstract:

BACKGROUND:Cytokines can be strong potentiators for a tumour vaccine, but they have very short life in vivo when administered as a solution.
AIMS:To evaluate the slow release of interleukin 2 from a cytokine-vehicle in vitro and in vivo and to evaluate the anti-tumour activity of a new tumour vaccine in vivo.
METHODS:The tumour vaccine was composed of formalin-fixed Hepa 1-6 hepatoma tissue fragments, tuberculin and a lipid based vehicle containing granulocyte-macrophage colony-stimulating factor and interleukin 2. The quantity of interleukin 2 release from the cytokine-vehicle in vitro and in vivo was determined by a proliferation assay with CTLL-2 cell line. Hepa 1-6 hepatoma model system with C57BL/6J mice was used to examine protective and therapeutic anti-tumour effect of the vaccine.
RESULTS:Release of interleukin 2 from the cytokine-vehicle lasted 5 days in vitro and 3 days in vivo. The vaccine protected 67% of mice from a Hepa 1-6 cell challenge and had a therapeutic effect by prolonging the life span of mice bearing established Hepa 1-6 tumours of 5 mm in diameter. Of the treated mice, 20% became completely tumour-free.
CONCLUSIONS:Formalin-fixed tumour fragments and cytokines in controlled-release vehicle are useful in the rational design of tumour vaccines

注:弊社は病院やクリニックではなくバイオ企業であるため、症例報告や論文内容のWeb掲載は許容されています。

ご相談は無料です。
お気軽にお問い合わせください。